Review Articles

Jacinto FV, Esteller M.

Mutator pathways unleashed by epigenetic silencing in human cancer.

Mutagenesis. 2007;22(4):247-53. Review.

Shi H, Wang MX, Caldwell CW

CpG islands: their potential as biomarkers for cancer.

Expert Rev Mol Diagn. 2007;7(5):519-31

Smith LT, Otterson GA, Plass C

Unraveling the epigenetic code of cancer for therapy.

Trends Genet. 2007;(9):449-56..

Ibáñez de Cáceres I, Cairns P.

Methylated DNA sequences for early cancer detection, molecular classification and chemotherapy response prediction.

Clin Transl Oncol. 2007;(7):429-37.

Shames DS, Minna JD, Gazdar AF.

Methods for detecting DNA methylation in tumors: from bench to bedside.

Cancer Lett. 2007;251(2):187-98.

Esteller M.

Epigenetic gene silencing in cancer: the DNA hypermethylome.

Hum Mol Genet. 2007;16 Spec No 1:R50-9.

Herceg Z.

Epigenetics and cancer: towards an evaluation of the impact of environmental and dietary factors.

Mutagenesis. 2007 Mar;22(2):91-103.

Shames DS, Minna JD, Gazdar AF.

DNA methylation in health, disease, and cancer.

Curr Mol Med. 2007;7(1):85-102.

Additional Review Articles

Baylin SB, Ohm JE.
Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction?
Nat Rev Cancer. 2006;6(2):107-16.

Esteller M.
Epigenetics provides a new generation of oncogenes and tumour-suppressor genes.
Br J Cancer. 2006;94(2):179-83.

Baylin SB.
DNA methylation and gene silencing in cancer.
Nat Clin Pract Oncol. 2005;2 Suppl 1(S1):S4-S11.

Jones PA.
Overview of cancer epigenetics.
Semin Hematol. 2005;42(2 Suppl 2):S3-8.

Ballestar E, Esteller M.
The epigenetic breakdown of cancer cells: from DNA methylation to histone modifications.
Prog Mol Subcell Biol. 2005;38:169-81.

Laird PW.
Cancer epigenetics.
Hum Mol Genet. 2005;14 (1):65-76.

Herman JG, Baylin S.
Gene silencing in cancer in association with promoter hypermethylation.
NEJM 2003;349(21):2042-2053.

Brock MV, Hooker CM, Yung R, Guo M, Han Y, Ames SE, Chang D, Yang SC, Mason D, Sussman M, Baylin SB, Herman JG.
Can we improve the cytologic examination of malignant pleural effusions using molecular analysis?
Ann Thorac Surg. 2005;80(4):1241-7.

Robertson KD.
DNA methylation and human disease.
Nat Rev Genet. 2005;6(8):597-610.

Esteller M.
Aberrant DNA methylation as a cancer-inducing mechanism.
Annu Rev Pharmacol Toxicol. 2005;45:629-56.

Chen WY, Baylin SB.
Inactivation of tumor suppressor genes: choice between genetic and epigenetic routes.
Cell Cycle. 2005 (1):10-2.

Das PM, Singal R.
DNA methylation and cancer
J Clin Oncol. 2004;22(22):4632-42. Review.

Levenson VV.
DNA methylation biomarkers of cancer: moving toward clinical application.
Pharmacogenomics. 2004;5(6):699-707. Review.

Feinberg AP, Tycko B.
The history of epigenetics.
Nature Reviews | Cancer 2004;4:143-152

Esteller M.
Relevance of DNA methylation in the management of cancer.
Lancet 2003;4:351-357

Middleton MR, Margison GP.
Improvement of chemotherapy efficacy by inactivation of a DNA-repair enzyme.
Lancet 2003;4:37-44

Paz MF, Fraga, MF, Avila S, Guo M, Pollan M, Herman JG, Esteller M.
A systematic profile of DNA Methylation in human cancer cell lines

Cancer Res. 2003;63:1114-21

Iacopetta B.
Aberrant DNA methylation: Have we entered the era of more than one type of colorectal cancer?
Am. J. Path. 2003;162(4):1043-1045.

Sidransky D.
Emerging molecular markers of cancer.
Nature Reviews | Cancer 2002;2:210-219.

Baylin, SB, Belinsky SA, Herman JG.
Aberrant methylation of gene promoters in cancer-concepts, misconcepts, and promise.
J Natl Cancer Inst. 2000;92(18):1460-1.

Herman JG, Baylin SB.
Promoter-region hypermethylation and gene silencing in human cancer.
Curr Top Microbiol Immunol. 2000;249:35-54.

Baylin SB, Herman JG.
DNA hypermethylation in tumorigenesis: epigenetics joins genetics.
Trends Genet. 2000;16(4):168-74.

Herman JG.
Hypermethylation and tumor suppressor genes in cancer.
Cancer Biology 1999;9:359-367.